Staff

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical...

NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin

CARMEL, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell...

error: Content is protected !!